netFormulary Pan Mersey Area Prescribing Committee NHS
 
 Search
 Results

Looking for Adalimumab found 27 matches

Formulary items 4 matches
Sub Section Title / notes 3  matches
   
Formulary BNF Category
  Adalimumab Drugs affecting the immune response - 13.05.03
  Adalimumab Cytokine modulators - 10.01.03
  Adalimumab Cytokine inhibitors - 01.05.03
  Adalimumab Additional treatments used in the management of ophthalmic conditions not listed in BNF chapter 11 - 11.10
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section ADALIMUMAB injection (Humira®) in rheumatological conditions Pan Mersey Area Prescribing Committee Policy Statement (10.01.03)
link in subsection Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143) Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)  (10.01.03)
link in drug section NICE TA 146: Adalimumab for the treatment of adults with psoriasis  (13.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in subsection NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (2015) (10.01.03)
link in subsection NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.10)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)
link in subsection Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199) National Institute for Health and Care Excellence Technology Appraisal (10.01.03)
link in subsection Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130) National Institute for Health and Care Excellence Technology Appraisal  (10.01.03)

SubSection Titles / notes  
Archive documents | G H I - (30.03)
Preparations for psoriasis - (13.05.02)
STATIC LIST | A B C - (29.01)

 

netFormulary